Спасибо за дополнение!
На всякий случай приведу ссылки на статьи [
Ссылки доступны только зарегистрированным пользователям ] и [
Ссылки доступны только зарегистрированным пользователям ].
Отдельно упомяну о необходимости учитывать вид исходной опухоли при планировании обследования и возможной терапии дефицита ГР:
Цитата:
Timing of Growth Hormone Tests and Therapy
Testing for GH deficiency should be initiated at a time when GH therapy is considered safe. GH therapy should be avoided in the first 2–3 years after completion of cancer treatment, when the chance of cancer recurrence is greatest. Despite the lack of proof of a causal relationship between GH therapy and tumor recurrence, replacement therapy offered within this time period might inadvertently be associated with tumor recurrence and death.[71] Nonetheless, if the need to achieve normal final height is urgent, implementation of GH therapy might be considered as soon as 1 year after cancer treatment, depending on cancer type, severity of short stature, age and pubertal status. GH therapy is offered routinely after 2 years by some centers without recourse to GH tests or evidence of impaired growth if the HPA received a dose above 30 Gy. Alternatively, some clinicians consider replacement therapy when GH deficiency is established biochemically, regardless of growth rate.
|